# AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

> **NCT06511869** · PHASE2 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** AZD4205

## Key facts

- **NCT ID:** NCT06511869
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-17
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511869, "AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06511869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*